Oriana Hawkins
Last active: 6/14/2013

Notice: This account is no longer active within Vanderbilt records. However, it is still maintained here since it is part of the research network. If you are the owner and would like to update the information, please contact us.

Oriana E Hawkins, Ph.D.

Official Affiliation: Cancer Biology

Profile

My research interests include exploring the interplay between tumor cells, stroma and the immune system in early tumor development, progression and metastasis. My work focuses on understanding the contribution of cytokine/chemokine signaling in the development of a pro-tumor versus an anti-tumor immune response.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. Crowder SW, Horton LW, Lee SH, McClain CM, Hawkins OE, Palmer AM, Bae H, Richmond A, Sung HJ (2013) FASEB J 27(7): 2788-98
    › Primary publication · 23568779 (PubMed) · PMC3688746 (PubMed Central)
  2. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2013) EMBO Mol Med 5(1): 149-66
    › Primary publication · 23180582 (PubMed) · PMC3569660 (PubMed Central)
  3. INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Yang J, Kantrow S, Sai J, Hawkins OE, Boothby M, Ayers GD, Young ED, Demicco EG, Lazar AJ, Lev D, Richmond A (2012) Cancer Res 72(18): 4682-95
    › Primary publication · 22836752 (PubMed) · PMC3459578 (PubMed Central)
  4. RAF265 inhibits the growth of advanced human melanoma tumors. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2012) Clin Cancer Res 18(8): 2184-98
    › Primary publication · 22351689 (PubMed) · PMC3724517 (PubMed Central)
  5. The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Hawkins OE, Richmond A (2012) Breast Cancer Res 14(1): 103
    › Primary publication · 22293321 (PubMed) · PMC3496126 (PubMed Central)
  6. TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells. Weidanz JA, Hawkins O, Verma B, Hildebrand WH (2011) Int Rev Immunol 30(5-6): 328-40
    › Primary publication · 22053972 (PubMed) · PMC3405915 (PubMed Central)
  7. Differential MHC class I expression in distinct leukocyte subsets. Greene JM, Wiseman RW, Lank SM, Bimber BN, Karl JA, Burwitz BJ, Lhost JJ, Hawkins OE, Kunstman KJ, Broman KW, Wolinsky SM, Hildebrand WH, O'Connor DH (2011) BMC Immunol : 39
    › Primary publication · 21762519 (PubMed) · PMC3155488 (PubMed Central)
  8. An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. Hawkins O, Verma B, Lightfoot S, Jain R, Rawat A, McNair S, Caseltine S, Mojsilovic A, Gupta P, Neethling F, Almanza O, Dooley W, Hildebrand W, Weidanz J (2011) J Immunol 186(11): 6607-16
    › Primary publication · 21515791 (PubMed)
  9. Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities. Southwood S, Solomon C, Hoof I, Rudersdorf R, Sidney J, Peters B, Wahl A, Hawkins O, Hildebrand W, Mothé BR, Sette A (2011) Immunogenetics 63(5): 275-90
    › Primary publication · 21274527 (PubMed) · PMC3068250 (PubMed Central)
  10. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. Verma B, Hawkins OE, Neethling FA, Caseltine SL, Largo SR, Hildebrand WH, Weidanz JA (2010) Cancer Immunol Immunother 59(4): 563-73
    › Primary publication · 19779714 (PubMed)
  11. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. Loffredo JT, Sidney J, Bean AT, Beal DR, Bardet W, Wahl A, Hawkins OE, Piaskowski S, Wilson NA, Hildebrand WH, Watkins DI, Sette A (2009) J Immunol 182(12): 7763-75
    › Primary publication · 19494300 (PubMed) · PMC2701622 (PubMed Central)
  12. Identification of breast cancer peptide epitopes presented by HLA-A*0201. Hawkins OE, Vangundy RS, Eckerd AM, Bardet W, Buchli R, Weidanz JA, Hildebrand WH (2008) J Proteome Res 7(4): 1445-57
    › Primary publication · 18345606 (PubMed)

Links

Featured Affiliation

No featured affiliations

    View all affiliations

    Contact Information

    No address provided
    615-343-7780 (p)
    Email

    Keywords & MeSH Terms

    MeSH terms are retrieved from PubMed records. Learn more.

    Key: MeSH Term Keyword

    Apoptosis Azepines Base Sequence Blotting, Western breast cancer Cell Differentiation Cell Hypoxia Cells, Cultured Cell Survival Cellular Senescence Disease Models, Animal Extracellular Signal-Regulated MAP Kinases Flow Cytometry Gene Expression Regulation Histocompatibility Antigens Class I Humans Immunoenzyme Techniques immunotherapy Intramolecular Oxidoreductases MAP Kinase Signaling System melanoma Mesenchymal Stem Cells Mice Mutation NF-kappa B Nuclear Proteins Peptide Library Protein Binding Reactive Oxygen Species Real-Time Polymerase Chain Reaction Transcription Factors Transplantation, Heterologous Tumor Immunology Virus Replication